Yazan Assaf

Yazan Assaf

Auto-generated profile, based on publicly available information

Yazan Assaf

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2021 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
TSTareq Al Saadi
Tareq Al Saadi
YAYazan Assaf
Yazan Assaf
MFMedhat Farwati
Medhat Farwati
KTKhaled Turkmani
Khaled Turkmani
AAAhmad Al-Mouakeh
Ahmad Al-Mouakeh
MMMohammed E Madmani
Mohammed E Madmani

1 June 2021 in Hypertension
Verified
Journal Article
Closed access
PDF file
YAYazan Assaf
Yazan Assaf
ABAhmad Barout
Ahmad Barout
AAAhmad Alhamid
Ahmad Alhamid
AAAhmad Al-Mouakeh
Ahmad Al-Mouakeh
MLMaria Barillas Lara
Maria Barillas Lara
TAThomas G. Allison
Thomas G. Allison
We sought to update norms for peak systolic blood pressure (SBP) on the graded exercise test and examine its prognostic value in patients without baseline cardiovascular disease. Mayo graded exercise test data (1993–2010) were reviewed for nonimaging tests using Bruce protocol, selecting Minnesota residents 30 to 79 years without baseline cardiovascular disease. We formed a pure cohort of patients without factors significantly affecting peak SBP to determine peak SBP percentile norms by age and sex. Then we divided the full cohort of patients into 5 groups based on peak SBP percentiles: low (90th). The relationship between peak SBP and mortality was tested using Cox regression adjusting for age, sex, and comorbidities affecting peak SBP or mortality. We identified 20 760 eligible patients with 7313 females (35%) and mean age 51.5±10.7 years. Our pure cohort included 7810 patients. Over 12.5±5.0 years follow-up, there were 1582 deaths, including 541 cardiovascular deaths. In the fully adjusted model, low-peak SBP was associated with increased total mortality (heart rate, 1.41 [1.19–1.66], P <0.0001) and cardiovascular mortality (heart rate, 1.54 [1.16–2.03], P =0.001), while borderline low-peak SBP was associated with increased cardiovascular mortality only (heart rate, 1.36 [1.02–1.81], P =0.027). High peak SBP was associated with increased total mortality only in the age-sex adjusted model (heart rate, 1.18 [1.02–1.36], P =0.026), not after full adjustment. We conclude that low exercise peak SBP is an independent predictor of higher total and cardiovascular mortality.

1 September 2023 in Mayo Clinic Proceedings
Verified
Journal Article
Open access
NSNóra Sydó
Nóra Sydó
UIUmair Iftikhar
Umair Iftikhar
ECEmese Csulak
Emese Csulak
AMAlejandra Meza
Alejandra Meza
BMBéla Merkely
Béla Merkely
TAThomas G. Allison
Thomas G. Allison
To identify specific causes of death and determine the prevalence of noncardiovascular (non-CV) deaths in an exercise test referral population while testing whether exercise test parameters predict non-CV as well as CV deaths. Non-imaging exercise tests on patients 30 to 79 years of age from September 1993 to December 2010 were reviewed. Patients with baseline CV diseases and non-Minnesota residents were excluded. Mortality through January 2016 was obtained through Mayo Clinic Records and the Minnesota Death Index. Exercise test abnormalities included low functional aerobic capacity (ie, less than 80%), heart rate recovery (ie, less than 13 beats/min), low chronotropic index (ie, less than 0.8), and abnormal exercise electrocardiogram (ECG) of greater than or equal to 1.0 mm ST depression or elevation. We also combined these four abnormalities into a composite exercise test score (EX_SCORE). Statistical analyses consisted of Cox regression adjusted for age, sex, diabetes, hypertension, obesity, current and past smoking, and heart rate-lowering drug. The study identified 13,382 patients (females: n=4736, 35.4%, 50.5±10.5 years of age). During 12.7±5.0 years of follow-up, there were 849 deaths (6.3%); of these 162 (19.1%) were from CV; 687 (80.9%) were non-CV. Hazard ratios for non-CV death were significant for low functional aerobic capacity (HR, 1.42; 95% CI, 1.19 to 1.69; P<.0001), abnormal heart rate recovery (HR, 1.36; 95% CI, 1.15 to 1.61; P<.0033), and low chronotropic index (HR, 1.49; 95% CI, 1.26 to 1.77; P<.0001), whereas abnormal exercise ECG was not significant. All exercise test abnormalities including EX_SCORE were more strongly associated with CV death versus non-CV death except abnormal exercise ECG. Non-CV deaths predominated in this primary prevention cohort. Exercise test abnormalities not only predicted CV death but also non-CV death.

17 April 2018 in Cardiology and Therapy
Verified
Journal Article
Open access
PDF file
YAYazan Assaf
Yazan Assaf
MNMaher Nasser
Maher Nasser
HJHani Jneid
Hani Jneid
DODavid Ott
David Ott
Right ventricular (RV) myxomas are extremely rare, but may have dreadful clinical sequelae including pulmonary embolism (PE). We present a case of a patient who had an RV myxoma that was attached to the tricuspid valve, and therefore could not be resected completely during surgery, and remnants of the tumor were seen on transthoracic echocardiogram during post-operative follow-up. Five months after surgery, the patient had PE, which could be due to tumor emboli or thromboemboli. Since repeat surgical resection was not feasible, the patient was started on warfarin. The patient is doing well and has had no PE recurrence over the past 20 months of follow-up. We have complemented the current case report with a comprehensive literature search and review on RV myxomas associated with PE in order to shed light on this uncommon but potentially lethal disorder. We concluded that right-sided cardiac myxomas, including RV myxomas, should be considered while dealing with PE, particularly in young patients with no risk factors, and that follow-up with echocardiography after surgery is important due to the possibility of recurrence, especially if complete resection was difficult to perform.

15 April 2022 in International Journal of Cardiology
Verified
Journal Article
Closed access
AEAyman Elbadawi
Ayman Elbadawi
BTBryan E-Xin Tan
Bryan E-Xin Tan
YAYazan Assaf
Yazan Assaf
MMMichael Megaly
Michael Megaly
MSMohamed Shokr
Mohamed Shokr
ASAhmed Soliman
Ahmed Soliman

5 August 2022 in The American Journal of Cardiology
Verified
Journal Article
Closed access
AEAyman Elbadawi
Ayman Elbadawi
BTBryan E-Xin Tan
Bryan E-Xin Tan
YAYazan Assaf
Yazan Assaf
MEMohammed Elzeneini
Mohammed Elzeneini
BBBasarat Baig
Basarat Baig
MMMamas A. Mamas
Mamas A. Mamas